Home/Pipeline/AVGN7 + AVGND

AVGN7 + AVGND

Duchenne Muscular Dystrophy (DMD)

Pre-clinicalActive

Key Facts

Indication

Duchenne Muscular Dystrophy (DMD)

Phase

Pre-clinical

Status

Active

Company

AAVogen

About AAVogen

AAVogen is a private, preclinical-stage biotech focused on creating safer, more effective AAV-based gene therapies for muscle disorders. Its core technology involves muscle-tropic AAV vectors engineered to avoid the toxicities seen in other gene therapies, aiming to durably increase muscle mass and strength. The pipeline features AVGN7 for IBM, heart failure, and sarcopenic obesity, and a combination therapy (AVGN7+AVGND) for DMD. Founded by a family personally affected by muscle wasting diseases, the company operates with a lean, virtual model, leveraging key external partners for research, manufacturing, and regulatory strategy.

View full company profile

Therapeutic Areas

Muscle Wasting Diseases Neuromuscular Diseases Cardiovascular Disease

Other Duchenne Muscular Dystrophy (DMD) Drugs

Drug	Company	Phase	Status
DT-DEC01	Dystrogen Therapeutics	Phase 1	Active (Dose Escalation)
Skeletal Muscle Regeneration Program	IPS HEART	Pre-clinical	Active
KYMBEE (deflazacort)	Upsher-Smith	Approved	Active
ALY688ER	Allysta Pharmaceuticals	Phase 1	Active
Myomatrix Stabilization Program	Strykagen	Preclinical	Active
RIPPLE™ (implied)	SonoThera	Preclinical	Active
Vamorolone (AGAMREE)	ReveraGen BioPharma	Approved	Active
AGAMREE (vamorolone)	Catalyst Pharmaceuticals	Marketed	Commercial; Long-term safety monitored via SUMMIT Registry
EDG-5506	Edgewise Therapeutics	Phase 2	Active
ELEVIDYS (delandistrogene moxeparvovec-rokl)	Sarepta Therapeutics	Marketed / Phase 3	FDA Accelerated Approval; Confirmatory trial ongoing
SRP-5051 (vesleteplirsen)	Sarepta Therapeutics	Phase 2	Active (Next-gen PPMO)
EXONDYS 51 (eteplirsen)	Sarepta Therapeutics	Marketed	FDA Approved